ZTS Stock Recent News

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zoetis Inc. is the dominant animal health company, growing market share, revenue, and margins, now trading at a multi-year low valuation. Fundamentals remain strong: rising EPS, aggressive buybacks, and a shareholder yield of 3.2% with robust secular tailwinds supporting long-term growth. Key franchises (Simparica, Apoquel, Librela) are expanding, protected by patents, into the 2030s-2040s, with further growth potential from under-penetrated markets.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

JPMorgan upgraded Phibro Animal Health Corporation PAHC, citing strong execution following its $350 million acquisition of Zoetis' medicated feed additive and water-soluble product portfolio.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or Zoetis (ZTS).

I am an adherent to the Gardner-Kretzmann Continuum's strategy of owning at least one stock for each year of your age. Because of this notion, I have 37 "core" holdings that I try to add to consistently over time.

For investors focused on the long game, there is little reason to sell -- at least, so long as a company generates solid returns through consistently improving financial results, regularly increases its dividend (if it pays one), and maintains strong growth prospects. Although it's sometimes difficult to find corporations that can do all that over long periods, stocks of this caliber do exist.

Zoetis remains a compelling long-term investment, driven by strong growth in companion animal products and a resilient pet care market. Despite recent underperformance and valuation concerns, Zoetis's leadership, scale, and innovation position it well against new competitors. Financials show steady revenue, profit, and dividend growth, with management raising full-year guidance and focusing on expanding key product lines.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentat.